Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Profit After Tax: 2009-2024

Historic Profit After Tax for Gyre Therapeutics (GYRE) over the last 16 years, with Dec 2024 value amounting to $17.9 million.

  • Gyre Therapeutics' Profit After Tax rose 107.84% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year increase of 114.12%. This contributed to the annual value of $17.9 million for FY2024, which is 120.94% up from last year.
  • Per Gyre Therapeutics' latest filing, its Profit After Tax stood at $17.9 million for FY2024, which was up 120.94% from -$85.5 million recorded in FY2023.
  • Gyre Therapeutics' 5-year Profit After Tax high stood at $17.9 million for FY2024, and its period low was -$87.9 million during FY2021.
  • Its 3-year average for Profit After Tax is -$21.1 million, with a median of $4.3 million in 2022.
  • Its Profit After Tax has fluctuated over the past 5 years, first tumbled by 2,081.46% in 2023, then soared by 120.94% in 2024.
  • Over the past 5 years, Gyre Therapeutics' Profit After Tax (Yearly) stood at -$56.2 million in 2020, then slumped by 56.35% to -$87.9 million in 2021, then spiked by 104.91% to $4.3 million in 2022, then plummeted by 2,081.46% to -$85.5 million in 2023, then soared by 120.94% to $17.9 million in 2024.